Samantha Semenkow
Stock Analyst at Citi
(0.34)
# 4,505
Out of 5,078 analysts
224
Total ratings
40.8%
Success rate
-4.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Rated: Buy | $1,301 | $873.71 | +48.91% | 22 | Oct 21, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $97 → $119 | $90.33 | +31.74% | 4 | Oct 21, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $21 | $5.10 | +311.76% | 13 | Oct 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $143 | $89.27 | +60.19% | 4 | Oct 14, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | $68 | $24.05 | +182.74% | 16 | Oct 13, 2026 | |
| ROIV Roivant Sciences | Rated: Buy | $46 | $36.49 | +26.06% | 7 | Oct 12, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $33 | $14.37 | +129.65% | 6 | Oct 6, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | $151 | $37.22 | +305.70% | 12 | Oct 5, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $17 | $13.88 | +22.48% | 7 | Sep 17, 2026 | |
| DNTH Dianthus Therapeutics | Initiated Coverage: Buy | $156 | $76.78 | +103.18% | 1 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.47 | +580.27% | 12 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $97 | $21.19 | +357.76% | 7 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 → $52 | $37.00 | +40.54% | 5 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $19 | $3.18 | +497.48% | 5 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $61 | $28.41 | +114.71% | 16 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $2.35 | +495.74% | 19 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $2.84 | +287.32% | 2 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 | $1.25 | +220.00% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $1.74 | +532.18% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $6 | $11.85 | -49.37% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.33 | +415.02% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4.25 | $3.67 | +15.80% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $5 | $2.40 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $17.08 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.7 → $0.75 | $0.000001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $24.03 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $7 | $3.08 | n/a | 2 | Jul 21, 2021 |
argenx SE
Oct 21, 2026
Rated: Buy
Price Target: $1,301
Current: $873.71
Upside: +48.91%
Spyre Therapeutics
Oct 21, 2026
Reiterated: Buy
Price Target: $97 → $119
Current: $90.33
Upside: +31.74%
BioAge Labs
Oct 14, 2026
Reiterated: Buy
Price Target: $21
Current: $5.10
Upside: +311.76%
Rhythm Pharmaceuticals
Oct 14, 2026
Reiterated: Buy
Price Target: $143
Current: $89.27
Upside: +60.19%
Beam Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $68
Current: $24.05
Upside: +182.74%
Roivant Sciences
Oct 12, 2026
Rated: Buy
Price Target: $46
Current: $36.49
Upside: +26.06%
Cullinan Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $33
Current: $14.37
Upside: +129.65%
Nektar Therapeutics
Oct 5, 2026
Reiterated: Buy
Price Target: $151
Current: $37.22
Upside: +305.70%
Biohaven
Sep 17, 2026
Reiterated: Buy
Price Target: $17
Current: $13.88
Upside: +22.48%
Dianthus Therapeutics
Sep 4, 2026
Initiated Coverage: Buy
Price Target: $156
Current: $76.78
Upside: +103.18%
Sep 1, 2026
Reiterated: Buy
Price Target: $10
Current: $1.47
Upside: +580.27%
Aug 10, 2026
Reiterated: Buy
Price Target: $97
Current: $21.19
Upside: +357.76%
Jul 31, 2026
Reiterated: Buy
Price Target: $46 → $52
Current: $37.00
Upside: +40.54%
Jul 31, 2026
Reiterated: Buy
Price Target: $24 → $19
Current: $3.18
Upside: +497.48%
Jun 30, 2026
Reiterated: Buy
Price Target: $57 → $61
Current: $28.41
Upside: +114.71%
Jun 30, 2026
Reiterated: Buy
Price Target: $14
Current: $2.35
Upside: +495.74%
Jun 15, 2026
Reiterated: Buy
Price Target: $11
Current: $2.84
Upside: +287.32%
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $1.25
Upside: +220.00%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $1.74
Upside: +532.18%
Mar 20, 2026
Reiterated: Sell
Price Target: $6
Current: $11.85
Upside: -49.37%
Mar 4, 2026
Reiterated: Buy
Price Target: $12
Current: $2.33
Upside: +415.02%
Nov 11, 2025
Reiterated: Hold
Price Target: $5 → $4.25
Current: $3.67
Upside: +15.80%
Mar 6, 2025
Reiterated: Buy
Price Target: $15 → $5
Current: $2.40
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $17.08
Upside: n/a
May 18, 2023
Reiterated: Hold
Price Target: $1.7 → $0.75
Current: $0.000001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $24.03
Upside: n/a
Jul 21, 2021
Reiterated: Buy
Price Target: $16 → $7
Current: $3.08
Upside: n/a